Director / PDMR Shareholding - NED Purchase of Shares
Belfast and London, 23 May 2024 - Diaceutics PLC (AIM: DXRX) ("Diaceutics" or the "Company"), a leading technology and solutions provider to the pharma and biotech industry announces that on 22 May 2024, Graham Paterson, a Non-Executive Director of Diaceutics, purchased 39,934 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.2889 per Ordinary Share. As a result of the purchase, Graham Paterson's shareholding in Diaceutics is 73,498 Ordinary Shares representing approximately 0.09% of the Company's issued share capital.
Enquiries:
| Diaceutics PLC | |
| Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer
| Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com |
| | |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Nick Harland | |
| Kate Hanshaw | |
| | |
| Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
| Caroline Forde | diaceutics@almastrategic.com |
| | |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Graham Paterson | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Non-Executive Director | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Purchase | |||||
| c. | Price(s) and volume(s) | | Share purchase: | | | | |
| | Price(s) | Volume(s) | | ||||
| £1.2889 | 39,934 | | |||||
| | |||||||
| d. | Date of the transaction | 22 May 2024 | |||||
| e. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.